Innovative path into China market – a deep dive into regulatory path into China market. Are you ready?
This is an update on China's recent regulatory reform from 2018. In the past 12 months, more draft regulations/guidelines have been finalized and gone into the implementation stage, which will change China's role in global drug development. Therefore, it is important to follow up to those changes, in order to fully explore China drug development potential. At the webinar, we will share insights on the following areas.
- Regulatory path for innovative medicine / devices in China
- China regulatory requirement timeline/costs compare to US / EU
- Updates on China Regulatory Reform
- Orphan drug path into China
Event details
|
DATE Tuesday, February 18, 2020 VENUE Webex TIME Berlin time 10AM – 11AM(China time 5PM – 6PM) RSVP This is a FREE event This webinar is in English VIP tickets priority for Lingmed current clients Please RSVP by Feb 17, 2020 |
PRESENTERS Lingling Cao, CEO & Founder Dr Dan Zhang, Guest speaker REGISTER +86 21 5386 3003 |
Agenda Berlin time @10:00 (China time 17:00)
| 10:00 - 10:10 | Linkedbio services & projects introductions | by LingLing Cao |
| 10:10 - 10:45 | Innovative path into China market – a deep dive into regulatory path into China market | by Dr Dan Zhang |
| 10:45 - 10:55 | Panel discussions | |
| 10:55 - 11:00 | Q&A |
Presenters
 |
Lingling Cao CEO & Founder Lingling has more than a decade of experience in the healthcare industry, especially in deal-making. She founded Lingmed, which aims to support BD professionals to make better decisions with intelligence databases and EU-China cross-border deals. Prior to her venture at Lingmed, she was a senior BD manager for Eli Lilly in Shanghai and a consultant for McKinsey in Germany |
 |
Dr Dan Zhang Guest speaker Dr. Zhang received his pre-med training from Peking University and MD from Peking Union Medical College in China. He continued his study at the Harvard School of Public Health in the US and received an MPH in Health Policy and Management. He then continued his training at the Wharton School of the University of Pennsylvania, where he obtained his MBA in Health Care Management in 1998. Dr Zhang was - Head of Clinical Development and Global Safety Assessment at Sigma-Tau Research Inc., - Vice President at the Quintiles Transnational Corp., Over the last 15 years, Dr. Zhang has provided services for the government and academic institutions in China. He is a member of the grant review committee for the National Key Drug Development Fund, jointly managed by the Ministry of Science & Technology (MOST), and the National Health and Family Planning Commission of China (NHFPC). He chaired the BayHelix CFDA working committee and works with the agency on development of technical guidelines. He was a member of the Overseas Expert Committee on New Drug R&D from MOST. He is senior consultant to the Chinese Academy of Medical Sciences and Peking Union Medical College. He was also a visiting professor at the Harbin Medical University of China, Nankai University, and Science and Technology University of South China. He is currently a senior consultant to the Chinese Academy of Medical Sciences and Peking Union Medical College. Dr. Zhang was an Executive Director of Sino-American Professional Pharmaceutical Society (SAPA), President (2006–2007) of the Chinese Biopharmaceutical Association-USA (CBA), a Board Director of BayHelix, and is currently Secretary General of the Thousand Talents Program. |